The FDA has authorized Pfizer Covid-19 vaccine booster shots for those 65+, immunocompromised people, and those at risk of infection. The announcement was made yesterday, and the Acting FDA Commissioner, Janet Woodcock, M.D, explained that those younger than 65 years old should consider getting the booster jab if they are immunocompromised, at risk of developing a severe form of the Covid-19 disease or if they are essential workers. Health providers, teachers, grocery workers, prison staff and nursing home staff, and others are among those who can get a booster shot.
FDA health experts will continue to analyze all data connected to the Covid-19 vaccines
Pfizer and BioNTech are not the only pharmaceutical companies that have submitted Covid-19 vaccination data to the FDA. Each company is conducting clinical trials for different age groups, and Pfizer wants the FDA to approve booster shots for all eligible people 16 years old or older.
Vaccine immunity drops after a few months
Recent studies concluded that the efficiency of the Pfizer Covid-19 vaccine drops to 83.7% after four to six months from the second jab. The effectiveness during the first two months after a person received two doses is 96.2%.
Israel is among many countries that have predominantly used the Pfizer vaccine, and many studies are analyzing the effectiveness of this vaccine against different variants of the SARS-CoV-2 virus. In other countries, such as the U.K, health experts were looking to determine if it would be beneficial to wait more between the two doses of the vaccine.
A new Covid-19 second-generation mRNA could be used for booster shots next year
Gritstone announced that a new second-generation mRNA vaccine might become available next year if the clinical trials show good results. The new vaccine, GRT-R910, will use a self-amplifying technology to boost the immune system and stop the virus from spreading.